Michael Grippo - Catalent Insider
Insider
Michael Grippo is Senior Vice President - Strategy and Corporate Development of Catalent since 2019.
Age | 55 |
Tenure | 6 years |
Phone | 732 537 6200 |
Web | https://www.catalent.com |
Michael Grippo Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Grippo against Catalent stock is an integral part of due diligence when investing in Catalent. Michael Grippo insider activity provides valuable insight into whether Catalent is net buyers or sellers over its current business cycle. Note, Catalent insiders must abide by specific rules, including filing SEC forms every time they buy or sell Catalent'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Grippo over three months ago Disposition of 1114 shares by Michael Grippo of Catalent subject to Rule 16b-3 |
Catalent Management Efficiency
Catalent's management efficiency ratios could be used to measure how well Catalent manages its routine affairs as well as how well it operates its assets and liabilities.Catalent currently holds 4.92 B in liabilities with Debt to Equity (D/E) ratio of 0.9, which is about average as compared to similar companies. Catalent has a current ratio of 2.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Catalent's use of debt, we should always consider it together with its cash and equity.
Similar Executives
Showing other executives | INSIDER Age | ||
Flavia Pease | Charles River Laboratories | 51 | |
Simon May | Bio Rad Laboratories | 52 | |
John CFA | Teleflex Incorporated | N/A | |
Jay White | Teleflex Incorporated | 51 | |
Molly Joseph | West Pharmaceutical Services | 46 | |
Dara Wright | Bio Rad Laboratories | 48 | |
Costa Panagos | IQVIA Holdings | N/A | |
Daniel Logue | Teleflex Incorporated | 50 | |
Robert Segura | West Pharmaceutical Services | N/A | |
Richard Luzzi | West Pharmaceutical Services | 72 | |
James Winters | Teleflex Incorporated | 48 | |
Victoria Creamer | Charles River Laboratories | 55 | |
Andrew Markwick | IQVIA Holdings | N/A | |
Matt Tomkin | Teleflex Incorporated | N/A | |
Kimberly MacKay | West Pharmaceutical Services | 58 | |
Jeffrey Spaeder | IQVIA Holdings | N/A | |
Trudy Stein | IQVIA Holdings | N/A | |
Cindy ReissClark | West Pharmaceutical Services | 50 | |
Ajit Ramalingam | Bio Rad Laboratories | 51 |
Management Performance
Return On Equity | -0.11 | |||
Return On Asset | -0.0018 |
Catalent Leadership Team
Elected by the shareholders, the Catalent's board of directors comprises two types of representatives: Catalent inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Catalent. The board's role is to monitor Catalent's management team and ensure that shareholders' interests are well served. Catalent's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Catalent's outside directors are responsible for providing unbiased perspectives on the board's policies.
Thomas Castellano, VP of Fin. and Investor Relations and Treasurer | ||
Paul Surdez, Vice Relations | ||
Joseph JD, General VP | ||
Tom PEng, President Delivery | ||
Trish Hunt, President Health | ||
Peter Zippelius, Independent Director | ||
David McErlane, Group Segment | ||
Steven Fasman, Senior Vice President General Counsel and Corporate Secretary | ||
Michael Hatzfeld, VP Officer | ||
Kay Schmidt, Senior Vice President - Technical Operations | ||
Karen Santiago, VP Office | ||
Jonathan Arnold, President - Oral & Specialty Delivery | ||
Ricky Hopson, Division President | ||
John MBA, Executive Board | ||
John Chiminski, Chairman of the Board, Chief Executive Officer | ||
Donald Morel, Independent Director | ||
John Greisch, Independent Director | ||
Gregory Lucier, Independent Director | ||
Rolf Classon, Independent Director | ||
Michael Barber, Independent Director | ||
Steven Esq, Corp VP | ||
Karen Flynn, President - Biologics and Chief Commercial Officer | ||
Michael Grippo, Senior Vice President - Strategy and Corporate Development | ||
Matti Masanovich, Senior CFO | ||
Julien Meissonnier, VP Officer | ||
Christa Kreuzburg, Independent Director | ||
Lisa Evoli, Senior Officer | ||
Madhavan Balachandran, Independent Director | ||
J Carroll, Independent Director | ||
Scott Gunther, Senior Vice President - Quality & Regulatory Affairs | ||
Wetteny Joseph, Chief Financial Officer, Senior Vice President | ||
Alessandro Maselli, Senior Vice President - Global Operations | ||
Dejan Lamesic, Head Development | ||
Ricci Whitlow, President - Clinical Supply Services | ||
Charles Lickfold, Senior Vice President, Chief Information Officer | ||
Aristippos Gennadios, President - Softgel & Oral Technologies | ||
Ricardo Pravda, Chief Human Resource Officer, Senior Vice President | ||
Jack Stahl, Lead Independent Director | ||
Z Mahdavi, Vice President of Open Innovation, Biologics, Cell and Gene Therapy | ||
Rosemary Crane, Independent Director |
Catalent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Catalent a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.11 | |||
Return On Asset | -0.0018 | |||
Profit Margin | (0.09) % | |||
Operating Margin | (0.07) % | |||
Current Valuation | 16.13 B | |||
Shares Outstanding | 181.51 M | |||
Shares Owned By Insiders | 0.50 % | |||
Shares Owned By Institutions | 87.80 % | |||
Number Of Shares Shorted | 14.74 M | |||
Price To Earning | 17.80 X |
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Catalent Stock
If you are still planning to invest in Catalent check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catalent's history and understand the potential risks before investing.
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |